Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy

What this episode covers

Visit https://www.peervoice.com/WAD860 to view the entire programme with slides. After completing “Raffaele Califano, MD - At the Frontline in ALK+ NSCLC: Practical Approaches to TKI Therapy”, participants will be able to: Describe the molecular aberrations and associated patient characteristics that influence response to treatment modalities in ALK-positive non-small cell lung cancer (NSCLC); Apply evidence-based approaches to balance the benefits of efficacy with risks of treatment-related toxicities in consolidated therapy combinations used in the management of ALK+ NSCLC; Formulate evidence-based strategies to identify and manage common and serious adverse events (AEs) associated with tyrosine kinase inhibitors (TKIs); and Apply evidence-based approaches to balance the benefit-risk ratio in the selection of appropriate treatment modalities for patients with ALK+ NSCLC and central nervous system (CNS) metastases.

Distinct summary based on available episode metadata or transcript content.